Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Canagliflozin Shows Significant Improvement in Glycemic Control against Placebo in PIII Study: MTPC
June 18, 2014
- Sawai Seeks US Approval for Livalo Generic, Submits ANDA
June 17, 2014
- Takeda to Withdraw US NDA for Anemia Drug, Cancel Deal with Affymax
June 17, 2014
- Meiji Seika Pharma, Fresenius Kabi Japan Terminate Alliance for Generic Drugs
June 17, 2014
- AZ to Shuffle Sales, Marketing Units, Focus on 3 Disease Areas
June 16, 2014
- Meiji Seika Pharma to Acquire Indian Generic Drug Maker Medreich for US$290 Million
June 16, 2014
- Ex-Novartis Employee Suspected of Manipulating the Number of Events in Sub-Analysis
June 13, 2014
- Teijin Now Largest Shareholder of Kyorin Holdings, Owns 19.12% Stake
June 13, 2014
- Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
- Valeant Wins US Approval for Kaken’s Onychomycosis Drug
June 12, 2014
- Daiichi Sankyo Initiates Development of Novel, Versatile Vaccine Adjuvant
June 12, 2014
- Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
- PII Study of Novel AD Treatment Begins in Japan: Fujifilm Holdings
June 11, 2014
- Novartis Pharma Collects Adverse Events of 10,000 Patients in Wake of Unreported ADRs in SIGN Trial
June 10, 2014
- Nippon Kayaku to Deploy RA Reps for Remicade Biosimilar
June 9, 2014
- April Ethical Drug Sales Down 3.5%, Hurt by Pullback from Pre-Tax Hike Demand: Crecon Report
June 9, 2014
- Results from PI/PII Studies of BBI608, BBI503 Presented at ASCO Annual Meeting: DSP
June 9, 2014
- AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
- Malignant STS Treatment Trabectedin Achieves Primary Endpoint in Domestic PII Clinical Trial: Taiho
June 6, 2014
- Nihon Chouzai to Provide Online Daily Pharmacy Prescription Trend Info.
June 6, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…